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Abstract 
 
Background: It is well known that gastric mucosa dysplasia and intestinal metaplasia are gastric precancerous lesions (GPL). 
Moxibustion treatment of Liangmen (ST21) and Zusanli (ST36) alleviated the inflammatory response and dysplasia of gastric 
mucosa in our previous study. The purpose of this study was to further examine the underlying mechanism of moxibustion 
treatment of ST21 and ST36 on GPL.  
Materials and Methods: Sixty SD rats were divided into five groups and rats with GPL were treated with either moxibustion 
(ST), moxibustion (Sham), or vitacoenzyme. B-cell lymphoma 2 (bcl-2), tumor protein p53 (P53) and cellular Myc (C-MYC), 
which are related to cell apoptosis, proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), 
argyrophilic nucleolar organizer region proteins (Ag-NORs), which are associated with cell proliferation, and cell signaling 
proteins, nuclear factor kappa B (NF-κB), epidermal growth factor receptor (EGFR) and phosphorylated extracellular signal 
regulated kinase (p-ERK), were measured after moxibustion treatment.  
Results: Compared with Control group, gastric mucosa in GPL group showed abnormal mucosal proliferation and pathological 
mitotic figure, the mRNA expression of bcl-2, P53 and C-MYC increased significantly (P < 0.01), the protein expression of 
PCNA, VEGF, Ag-NORs and the activity of NF-κB as well as EGFR/ERK signaling proteins also increased significantly (P < 
0.01). Moxibustion treatment decreased gastric mucosal proliferation and pathological mitotic figure, down-regulated the mRNA 
expression of bcl-2, P53, C-MYC (P < 0.01), decreased the protein expression of PCNA, VEGF, Ag-NORs and the activity of 
NF-κB as well as EGFR/ERK signaling proteins significantly (P < 0.01). But moxibustion treatment of Sham didn’t show the 
same effect on GPL.  
Conclusion: Moxibustion treatment inhibited cell apoptosis and reduced gastric mucosa dysplasia by inhibiting the expression of 
bcl-2, P53, C-MYC and decreased the activity of NF-κB as well as EGFR/ERK signaling proteins. 
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Introduction 
 
The typical pathological features of gastric precancerous lesions (GPL) are gastric mucosa dysplasia and intestinal metaplasia, 
which is closely associated with gastric carcinogenesis (Marques-Silva et al., 2014; Yoon and Kim, 2015). Helicobacter pylori 
infection, dietary habits, immune factors and duodenal reflux were involved in the mechanism of GPL (Pan et al., 2014). Present 
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medicine, including gastric mucosa protectant, proton pump inhibitors (PPIs) and antibiotic regimens for H. pylori eradication, are 
the most commonly used drugs for symptomatic treatment. However, the long-term use of PPIs is associated with side effects and 
may even increase the risk of carcinogenesis (Bahat, 2014; Florentin and Elisaf, 2012), and whether or not GPL are reversible by 
H. pylori eradication remains controversial (Park and Kim, 2015). Thus, an agent or therapy inhibiting GPL or preventing it 
worsening and accompanied by less side effects may represent an effective strategy to decrease morbidity from gastric cancer.  
Nuclear factor kappa B (NF-κB) and epidermal growth factor receptor (EGFR)/extracellular signal regulated kinase (ERK) 
activation have been proved to be the important step in gastric carcinogenesis progress (Osaki et al., 2011; Wang et al., 2004). 
Overexpression of NF-κ B contributes to enhanced gastric mucosal intestinal metaplasia and promoting the expression of B-cell 
lymphoma 2 (bcl-2), tumor protein p53 (P53) and cellular Myc (C-MYC) (Xu et al., 2001; Yang et al., 2004). EGFR is involved in 
control of gastric cell proliferation through activation of mitogen-activated protein kinase (MAPK) /ERK signaling pathway 
(Osaki et al., 2011), EGFR/ERK signaling activation will up-regulate the expression of cell proliferation-related proteins in gastric 
mucosa, such as proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF) and argyrophilic nucleolar 
organizer region proteins (Ag-NORs) (Moraes et al., 2013). Traditional Chinese medical therapies (including herbs, acupuncture 
and moxibustion) have been used to treat gastric diseases and its classical symptoms for two thousand years (Deng et al., 2012; 
Gao et al., 2005). Our previous study found that moxibustion of Liangmen (ST21) and Zusanli (ST36) alleviated the inflammatory 
response, down-regulated the expression of cell proliferative factors and decreased the level of serum carcino-embryonic antigen 
(CEA) in rats with GPL, suggesting a potentially protective role (Chen et al., 2013; Yang et al., 2015). Electro-acupuncture of 
ST21 and ST36 could inhibit the expression of bcl-2 and P53 and decrease the  apoptotic index, thereby play an important role in 
inhibiting cell apoptosis of gastric mucosa cells in rats with GPL (Yang et al., 2016). The aim of this study is to further investigate 
whether or not moxibustion of ST21 and ST36 protects gastric mucosa from carcinogenesis by targeting NF-κB and EGFR/ERK 
signaling pathway.  Vitacoenzyme is used as a positive control, which is a compound preparation derived from soybean 
fermentation, the main ingredients of which include riboflavin and its derivatives. It has been used as standard care to treat GPL 
and has been shown to inhibit the expression of epidermal growth factor receptor (EGFR), tumor protein p53 (P53) and C-MYC 
in the gastric mucosa (Shen et al., 2008). 
 
Materials and Methods  
Animals 
 
The animal experimental protocol was approved by the ethics committee for administration of experimental animals at the 
Medical College of Xiamen University. All animal procedures were performed in accordance with the regulations for the 
administration of affairs concerning experimental animals of the People’s Republic of China (November 14, 1988), which is 
consistent with the National Institute of Health “Guide for the Care and Use of Laboratory Animals”. Sixty healthy male specific 
pathogen free (SPF) grade Sprague-Dawley rats (100 ± 20 g, 4 weeks old) were provided by Xiamen University Laboratory 
Animal Center (certificate no. SCXK(Min)2008-0002) and housed in an air-conditioned atmosphere at 22°C and 50% relative 
humidity under a 12h dark-light cycle. Rats were allowed free access to food and water.  
 
Main reagents and instruments 
 
N-methyl-N`-nitro-N-nitrosoguanidine (MNNG, Cat.No. M0527) was bought from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, 
Japan). Anti-rat ELISA kits, including PCNA (Cat.No. BM0104), VEGF (Cat.No. EK0540) and Ag-NORs (Cat.No. EK0583), 
were bought from Wuhan boster biotechnology co., Ltd. (Wuhan, China). Rabbit anti rat EGFR (Cat.No. #2232) and 
phosphorylated ERK (p-ERK, Cat.No. #4376) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Goat 
anti rabbit IgG/HRP antibody (Cat.No. SAB3700946) was acquired from Sigma-Aldrich Co. (St. Louis, MO, USA). Instruments 
used in this experiment were as follow: Microplate reader (type 352, LabSystems Multiskan MS, Thermo Fisher Scientific Inc., 
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Waltham, MA, United States), Plate washer (type AC8, LabSystems Multiskan MS, Thermo Fisher Scientific Inc., Waltham, MA, 
United States), electrophoretic apparatus (Bio-Rad Laboratories, Inc., Hercules, California, USA), polymerase chain reaction 
system (Applied Biosystems co., Ltd., Waltham, MA, USA), electrophoresis groove (Beijing Donglin Changsheng biotechnology 
co., Ltd., Beijing, China). 
 
Rat model of GPL 
 
Model replication method was as follow: MNNG was mixed into the drinking water to arrive the final concentration of 
150μg/ml. The bottle with MNNG solution was wrapped with aluminum foil in order to protect it from light. Rats drink the fresh  
prepared MNNG solution freely for each day. At the same time, rat’s tail was clipped everyday. Last, irregular diet was carried out 
that rats got 2 days full feeding and 1 day no feeding recurrently. One rat was sacrificed every 2 weeks. The stomach section was 
stained with Hematoxylin and Eosin (HE) for routine pathological examination by light microscopy.  
 
Study design 
 
Figure 1 shows the study design for moxibustion treatment of GPL rats. Sixty rats were randomly assigned to two groups: 
Control group (n = 10) and Model replication group (n = 50). One rat of model replication group was sacrificed every 2 weeks to 
confirm the establishment of GPL model until the end of 20th week, and 10 rats had used in total. The other 40 rats were further 
randomly divided into 4 subgroups: GPL group (n = 10), GPL+Moxa(ST) group (n = 10), GPL+Moxa(Sham) group (n = 10) and 
GPL+vitacoenzyme group (n = 10). Moxibustion or drug treatment began from the second day of model replication and lasted for 
a total of 20 weeks. After the entire treatment course, all rats were killed simultaneously. The assessments including B-cell 
lymphoma 2 (bcl-2), P53, C-MYC, PCNA, VEGF, Ag-NORs, nuclear factor kappa B (NF-κB), EGFR and p-ERK measurement 
were performed on the next day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study design of moxibustion treatment in gastric precancerous lesions rats 
Control indicates the normal rats that their gastric mucosa doesn’t receive injury factors. Model replication is the rat model of 
Peng et al., Afr J Tradit Complement Altern Med. (2017) 14(2):148-160 
doi:10.21010/ajtcam.v14i2.16 
151 
 
gastric precancerous lesions (GPL). Some of them were used to test whether the model was established successfully every 2 
weeks. The other rats were divided into four groups: GPL rats without moxibustion treatment, GPL rats with moxibustion 
treatment on ST21 and ST36, GPL rats with moxibustion treatment on Sham, and GPL rats with vitacoenzyme treatment. The 
whole treatment course lasted for 20 weeks and then evaluated their effect. 
 
Moxibustion treatment 
 
In the GPL+Moxa(ST) group, moxibustion was applied at ST21 and ST36, located according to the textbook “Experimental 
Acupuncture & Moxibustion” (Li, 2003). ST21 was located at the intersection of midclavicular line and horizontal line of 3/4 
distance from the upper edge of the sternum to the external genital organs. ST36 was located ~5mm below the capitulum fibulae. 
In the GPL+Moxa(Sham) group, moxibustion was applied at 1cm lateral to ST21 and 1cm medial to ST36 (Figure S1). Rats in the 
GPL+Moxa(ST) and GPL+Moxa(Sham) groups were treated unilaterally with lit moxa respectively, from the second day of model 
replication. Prior to treatment, rats were fixed on boards and hair was clipped around the site of stimulations. Cottons with 
isoflurane were put into 50ml tubes, and rats inhaled isoflurane during moxibustion treatment. Lit moxa cones (width 1.75cm) 
were fixed using self-made moxibustion equipment to ensure the lit ends were 0.5cm away from the surface of the skin. 
Moxibustion was applied for 15 minutes every other day for 20 weeks in total and laterality was alternated with each session.  
 
Drug treatment 
 
Rats in the GPL+vitacoenzyme group received 216mg/kg vitacoenzyme (Cat.No. 010401; Hebei Huanhai Medicine Industry 
Co., Ltd, Cangzhou, China), which is equivalent to a clinical dose of 2.4g per day (by conversion according to body surface area). 
Vitacoenzyme tablets were dissolved in distilled water and administered intragastrically every day for 20 weeks. 
 
Specimen collection  
 
Keeping from food for 24h after 20weeks treatment, all rats were anesthetized intraperitoneally with 10% chloral hydrate, 
then were sacrificed and their stomachs were dissected. Each stomach was opened along the greater curvature and washed with 
1%DEPC ice-cold saline. Stomach specimens of curvatura gastrica minor were used for histopathological examination. Stomach 
specimens of sinus ventriculi with the size of 0.5cm×0.5cm was cut out and homogenized in saline, then the homogenate was put 
in refrigerator with the temperature of -20℃. Cell membrane was damaged by repeated freezing and thawing twice and the 
homogenate was centrifuged for 5 minutes (5000rpm/min, 2~8℃), then the supernatant fluid was used for protein test. 
Table 1: The primer sequence of GAPDH, bcl-2, P53, C-MYC and NF-κB 
Name Transcription Primer sequence 
GAPDH Forward 5’-AGAAGGCTGGGGCTCATTTG-3’ 
Reverse 5’-AGGGGCCATCCACAGTCTTC-3’ 
bcl-2 Forward 5’-GGCATCTTCTCCTTCCA-3’ 
Reverse 5’-AGTTCCTCCACCACCGT-3’ 
P53 Forward 5’-GCTTTGAGGTTCGTGTT-3’ 
Reverse 5’-CCTTCTTGGTCTTCGGG-3’ 
C-MYC Forward 5’-TCCAGCGAGAGACAGAG-3’ 
Reverse 5’-GCAGAGGCAGAGAACAC-3’ 
NF-κB Forward 5’-AATTTGGCTTCCTTTCTTGGCT-3’ 
Reverse 5’-CTGCGATACCTTAATGACAGCG-3’ 
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Note: GAPDH: glyceraldehyde-3-phosphate dehydrogenase; bcl-2: B-cell lymphoma 2; P53: tumor protein p53; C-MYC: cellular 
Myc; NF-κB: nuclear factor kappa B. 
 
Reverse transcription polymerase chain reaction (RT-PCR) 
 
Total RNA was extracted from gastric mucosal cells using TRIzol reagent and reverse-transcribed to cDNA using TOYOBO 
reverse transcription kits with cDNA Eraser, according to the manufacturer’s instructions. Then cDNA was synthesized using 
polymerase chain reaction system (Applied Biosystems co., Ltd., Waltham, MA, USA) at 30˚C for 10min, 42˚C for 60min, 99˚C 
for 5min, 4˚C for 5min. The full-length mRNA sequences of bcl-2, P53, C-MYC and NF-κB, were obtained from GenBank 
(http://www.ncbi.nlm.nih.gov/nucleotide), the sequence of primers were designed by using Primer 5.0 software (Applied 
Biosystems co., Ltd., Waltham, MA, USA) and synthesized by Beijing Dingguo Changsheng biotechnology co., Ltd. (Beijing, 
China) (see Table 1). Primers were used for a total of 35 cycles of PCR under the following parameters: pre-denaturation at 94˚C 
for 2 min, denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, extension at 72˚C for 30 sec, extension at 72˚C for  10 min. 
PCR product quality was monitored by post-PCR melt curve analysis. Each PCR product was subjected to electrophoresis on 2% 
agarose gel for 30 min, then ethidium bromide-stained bands were scanned and analysed. 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
Levels of the following proteins involved in cellular proliferation were measured in gastric tissue: PCNA, VEGF and 
Ag-NORs using rat-specific ELISA kits according to the manufacturer’s instructions (Wuhan Boster Biotechnology Co., Ltd., 
Wuhan, China). Briefly, samples were incubated for 30 min at 37℃, then were exposed to biotin-conjugated detection antibody 
and streptavidin-HRP respectively for 60 min at 37℃. Stabilised chromogen and stop solution were added to terminate the 
reaction, then plates were read at 450 nm (OD values) within 2 hours using a spectrophotometer. 
 
Western blotting 
 
Protein extracts were isolated from gastric mucosa in radio-immunoprecipitation assay buffer and protein concentrations 
were measured using the bicinchoninic acid (BCA) method. Protein supernatants (80μl) were separated on 10% 
SDS-polyacrylamide gel (SDS-PAGE) and transferred to nitrocellulose membranes. Rabbit anti-rat EGFR and p-ERK antibodies 
(1:1000; Cell Signaling Technology, Inc., Danvers, MA, USA) and goat anti-rabbit-IgG (H+L) antibody conjugated with 
horseradish peroxidase (1:5000; Sigma-Aldrich Co., St. Louis, MO, USA) were used as primary and secondary antibodies, 
respectively. The enhanced chemiluminescence (ECL) imaging method was used to facilitate the detection of protein bands. 
 
Statistical analysis 
 
All data were normally distributed and were expressed as mean ± standard deviation. Groups were compared by one-way 
analysis of variance (ANOVA) using the Statistical Package for the Social Sciences (SPSS) version 19.0 (SPSS Inc., Chicago, IL, 
USA). Fisher's test of least significant difference was used for post-hoc individual comparisons. P < 0.05 or 0.01 (two-sided) was 
considered to be statistically significant. 
 
Results  
Effect of moxibustion treatment on gastric mucosal pathology 
 
In order to investigate whether or not moxibustion treatment protected gastric mucosa in GPL rats effectively, we compared 
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the routine tissue slice of gastric mucosal tissue stained by HE from five groups and observed by light microscopy. At 12 weeks, 
the stomach of model replication group represents less gastric mucosal folds than that of control group, HE staining of the 
stomach showed gastric mucosal glands atrophy and decrease (Figure S2). At 20 weeks, the structure of the gastric mucosa in 
Control rats was intact and visible lesions were not evident microscopically. However, in untreated GPL rats, the structure of 
gastric mucosa was incomplete, irregular glands and divided cellular nuclei were evident under high magnification. Both 
moxibustion at ST21 and ST36 and vitacoenzyme treatment appeared to attenuate the severity of gastric mucosal lesions, because 
the arrangement of the gastric gland was more regular and glandular atrophy was not observed. By contrast, moxibustion at Sham 
points did not appear to protect the gastric mucosa from pathological lesions (Figure 2).  
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Figure 2: Histological evaluation of stomach sections of rats from different groups 
Figures in the left column show the low amplification (100×) of HE staining of representative gastric mucosa section from five 
groups: Control, gastric precancerous lesions (GPL), GPL+Moxa(ST), GPL+Moxa(Sham) and GPL+vitacoenzyme. Figures in the 
right column show the high amplification (400×) of five groups respectively. Black arrow point to representive features of gastric 
mucosa of each group. 
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Effect of moxibustion treatment on cell apoptosis-related proteins 
 
To explore the mechanism of moxibustion treatment on gastric precancerous lesions in vivo, we further study the cell 
apoptosis-related proteins by using RT-PCR. As shown in Figure 3, the mRNA expression of bcl-2, P53 and C-MYC in gastric 
mucosa of GPL group was significantly up-regulated when compared with the healthy Control group (2.95 ± 0.14 vs 2.18 ± 0.13, 
0.79 ± 0.05 vs 0.35 ± 0.03, 0.72 ± 0.10 vs 0.18 ± 0.01, respectively, P < 0.01). Moxibustion treatment at ST21 and ST36 
significantly down-regulated the expression of bcl-2, p53 and C-MYC in GPL rats relative to no treatment (1.18 ± 0.07 vs 2.95 ± 
0.14, 0.40 ± 0.05 vs 0.79 ± 0.05, 0.39 ± 0.03 vs 0.72 ± 0.10, respectively, P < 0.01), which was lower than that of moxibustion 
treatment at Sham points (1.18 ± 0.07 vs 2.73 ± 0.15, 0.40 ± 0.05 vs 0.79 ± 0.07, respectively, P < 0.01, and 0.40 ± 0.03 vs 0.52 ± 
0.08, P < 0.05). And drug treatment also showed the similar down-regulating effect on the mRNA expression of these cell 
apoptosis proteins.  
 
Figure 3: Effect of moxibustion treatment on the mRNA expression of apoptosis-related proteins in gastric precancerous lesions 
After 20 weeks of treatment, the mRNA expression of B-cell lymphoma 2 (bcl-2), tumor protein p53 (P53) and cellular Myc 
(C-MYC) in gastric mucosa of five groups: Control, GPL, GPL+Moxa(ST), GPL+Moxa(Sham) and GPL+vitacoenzyme (n=10), 
were detected by RT-PCR, the ratio of target gene and GAPDH was calculated. Results were compared by one-way analysis of 
variance and following with Fisher's Least Significant Difference test for individual comparisons. ★p < 0.05, ★★p < 0.01. 
 
Effect of moxibustion treatment on oncogenes relating to cell proliferation 
 
To explore the cell proliferation in gastric mucosa, we detected oncogenes relating to cell proliferation by using ELISA, 
RT-PCR and western blotting. Figure 4 showed the expression of various cell proliferation-related proteins in gastric mucosa 
measured by ELISA. Compared with Control group, the expression of PCNA, VEGF and Ag-NORs in GPL group increased about 
1.5-fold (2.92 ± 0.06 vs 1.76 ± 0.04 ng/ml, 235.29 ± 4.71 vs 150.28 ± 3.13 ng/ml, and 116.57 ± 2.72 vs 76.20 ± 2.65 ng/ml, 
respectively, P < 0.01). Moxibustion treatment at ST21 and ST36 for 20 weeks significantly reduced gastric mucosal expression 
of them (2.06 ± 0.09 vs 2.92 ± 0.06 ng/ml, 170.10 ± 4.31 vs 235.29 ± 4.71 ng/ml, 87.23 ± 2.91 vs 116.57 ± 2.72 ng/ml, 
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respectively, P < 0.01). Furthermore, their levels of GPL+Moxa (ST) group were significantly lower than that of GPL+Moxa 
(Sham) group (2.06 ± 0.09 vs 2.30 ± 0.09 ng/ml, 170.10 ± 4.31 vs 189.45 ± 5.04 ng/ml, 87.23 ± 2.91 vs 93.76 ± 3.75 ng/ml, 
respectively, P < 0.01).  
 
Figure 4: Effect of moxibustion treatment on cell proliferation-related proteins in gastric precancerous lesions 
After 20 weeks of treatment, the expression of proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor 
(VEGF) and argyrophilic nucleolar organizer region proteins (Ag-NORs) in gastric mucosa of five groups: Control, GPL, 
GPL+Moxa(ST), GPL+Moxa(Sham) and GPL+vitacoenzyme (n=10), were measured by ELISA. Results were compared by 
one-way analysis of variance and following with Fisher's Least Significant Difference test for individual comparisons. ★★p<0.01. 
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Effect of moxibustion treatment on NF-κB and EGFR/ERK signaling proteins  
 
To explore the intracellular signal pathway of moxibustion treatment on GPL, we further focused on the mRNA expression of 
NF-κB after 20 weeks treatment. The result demonstrated that the mRNA expression of NF-κB was significantly up-regulated in 
GPL group compared to Control group (0.84±0.06 vs 0.26±0.02, P < 0.01). Moxibustion treatment of ST21 and ST36 
down-regulated its expression in gastric mucosa significantly (0.43 ± 0.08 vs 0.84 ± 0.06, P < 0.01), and the effect was better than 
that of Sham points (0.43 ± 0.08 vs 0.76 ± 0.04, P < 0.01). Drug treatment didn’t show the effect of down-regulation of NF-κB in 
GPL (0.80 ± 0.08 vs 0.84 ± 0.06, P ＞ 0.05) (Figure 5A). 
EGFR/ERK signaling pathway is involved in control of gastric cell proliferation (Osaki et al., 2011). Here, we found that the 
expression of EGFR and p-ERK in GPL was significant higher than that in normal gastric mucosa (141.54 ± 4.93 vs 113.94 ± 3.26, 
60.46 ± 0.87 vs 0.17 ± 0.08, respectively, P < 0.01). Moxibustion treatment of ST21 and ST36 reduced their expression (115.83 ± 
3.11 vs 141.54 ± 4.93, 5.28 ± 1.16 vs 60.46 ± 0.87, respectively, P < 0.01), this effect was significant better than that of Sham 
points (115.83 ± 3.11 vs 134.01 ± 1.84, 5.28 ± 1.16 vs 34.06 ± 1.47, respectively, P < 0.01) (Figure 5B).  
 
Figure 5: Effect of moxibustion treatment on intracellular signaling proteins in gastric precancerous lesions 
After 20 weeks of treatment, the expression of nuclear factor kappa B (NF-κB), epidermal growth factor receptor (EGFR) and 
phosphorylated extracellular signal regulated kinase (p-ERK) in gastric mucosa of five groups: Control, GPL, GPL+Moxa(ST), 
GPL+Moxa(Sham) and GPL+vitacoenzyme (n=10), were detected by RT-PCR or Western blotting. Results were compared by 
one-way analysis of variance and following with Fisher's Least Significant Difference test for individual comparisons. ★★p<0.01. 
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n.s. means no significant difference. 
 
Discussion 
 
Gastric precancerous lesions include dysplasia and intestinal metaplasia of gastric mucosa, which is a high risk for gastric 
carcinogenesis in patients. The unique characteristics of gastric cancer are the intestinal and gastric types of cells in tumor. Gastric 
mucosal epithelial hyperplasia is considered as the earliest histological change in gastric carcinogenesis (Ming, 1998). Modern 
medical therapies, including H. pylori eradication, gastric acid inhibition and gastric mucosa protectant, are hard to cure this 
disease, and accompany with many side effects (Park and Kim, 2015). Moxibustion treatment is an important part of traditional 
Chinese therapies. Clinical studies have shown that moxibustion treatment have definite therapeutic effects on chronic atrophic 
gastritis, especially in improving the symptoms, and so can provide possibilities in reversing the pathologic changes of glandular 
atrophy and intestinal metaplasia (Gao et al., 2005). This study further provided evidence to prove that moxibustion treatment of 
ST21 and ST36 significant reduced gastric mucosa proliferation, pathological mitotic figure and glandular atrophy, the underlying 
mechanism was involved in promoting cell apoptosis and inhibiting oncogenes relating to cell proliferation by inhibiting the 
expression of bcl-2, P53, C-MYC and oncogenes relating to cell proliferation, the intracellular signaling pathway included NF-κB 
and EGFR/ERK signaling proteins. 
Cell apoptosis and the controlled genes have a profound effect on the malignant phenotype (Lowe and Lin, 2000). It is 
reported that over-expression of Bcl-2 protein is an early event in gastric tumorigenesis, before gastric dysplastic changes occur 
(Anagnostopoulos et al., 2005). P53 gene mutations were found in 35% of the gastritis samples and 45% of the intestinal 
metaplasia samples, suggesting a prominent role in gastic carcinogenesis (Morgan et al., 2003). And methylated pattern of 
C-MYC was abnormal in human gastric carcinogenesis (Fang et al., 1996). What’s more, the expression of bcl-2, P53 and C-MYC 
were negatively correlated with apoptotic index (Wu et al., 2012). As shown in our results, the mRNA expression of bcl-2, P53 
and C-MYC in GPL group was up-regulated significantly. Moxibustion and drug treatment for 20 weeks significant 
down-regulated the expression of bcl-2, P53 and C-MYC in gastric mucosa, which would decrease the inhibition effect of bcl-2, 
P53 and C-MYC, and helped to promote cell apoptosis as well as prevented the development of gastric tumorigenesis.  
The remarkable characteristics of cancer cells are malignant proliferation and invasive ability, PCNA, Ag-NORs and VEGF 
are usually recognized as useful markers for proliferation and invasion of cancer cells (Yu et al., 1992). PCNA and Ag-NORs are 
the intro-nuclear protein that are closely linked to the cell cycle, while VEGF contribute to form new vessels to nourish tumor or 
metastasize cancer cells (Moraes et al., 2013; Wang, 2014). Our results showed that the protein level of PCNA, Ag-NORs and 
VEGF increased significantly in gastric mucosa of rats fed with MNNG, moxibustion and drug treatment significant decreased 
their expression, suggesting that moxibustion treatment had the potential role of inhibiting malignant proliferation in GPL 
We further investigated the intra-cellular signaling pathway correlated with cell apoptosis and cell proliferation in GPL 
development. The expression of NF-kappaB/p65 were up-regulated at the early stage of gastric carcinogenesis, suggesting NF-κB 
activation was an important step in carcinogenesis progress (Wang et al., 2004). In our study, we found that the mRNA expression 
of NF-κB was up-regulated in gastric mucosa of GPL, moxibustion treatment play a significant role in inhibiting NF-κB 
expression. Transforming growth factor alpha (TGF-α)and other ligands bind to EGFR and trigger signaling cascades, such as 
MAPK. ERK1/2 is one part of MAPK, ERK phosphorylation stimulates transcription factors and following cell proliferation, so 
EGFR/ERK signaling pathway play an important role in gastric cancer development (Lurje and Lenz, 2009; Osaki et al., 2011). 
The protein expression of EGFR and p-ERK increased in gastric precancerous lesions, moxibustion treatment of ST21 and ST36 
significant inhibited their expression. 
Our study had several limitations. First, although moxibustion of Sham point had down-regulated the level of C-MYC, 
PCNA, VEGF, Ag-NORs and p-ERK/β-actin ratio, the protective effect showed significant decrease than that of ST point. The 
reason for the phenomenon may come from close moxibustion distance, some of the heat in Sham point spread to ST point. 
Second, we didn’t detect cell apoptosis in gastric mucosa directly by TUNEL staining. Third, intracellular signaling pathway 
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blockers or gene knockout technique should be used to prove molecular mechanism in the future.  
In conclusion, this study provided evidence for that moxibustion treatment of ST21 and ST36 had a potent gastro-protective 
effect against gastric precancerous lesions, the underlying mechanism was involved in inhibiting the expression of bcl-2, P53, 
C-MYC and decreasing the activity of NF-κB as well as EGFR/ERK signaling proteins, indicated that moxibustion treatment 
might be beneficial in preventing against gastric carcinoma. 
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